Santen Drug Patent Portfolio
Santen's Family Patents
Clinical Trials
Recent Clinical Trials by Santen:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China | Santen Pharmaceutical Co., Ltd. | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE3 |
| LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis. | Santen SAS | NA |
RECRUITING
(Apr 1, 2026)
| PHASE3 |
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List